On October 29, Iovance Biotherapeutics, Inc. rose 9.93% Overnight, trading at $16.28/share. The clearest catalyst was the company’s announcement that it would host a webcast to discuss positive data for tumor-infiltrating lymphocyte therapy in metastatic non-small cell lung cancer and its broader precision medicine strategy.
The event was scheduled for the same day and appears to have lifted attention toward the company’s pipeline beyond melanoma. Recent context also supports sentiment: Iovance Biotherapeutics, Inc. said in late September that it raised full-year revenue guidance to $410 million-$420 million from $350 million-$370 million, citing strong U.S. demand for Amtagvi and Proleukin, and it is set to report third-quarter results on November 5. Separately, the company recently reported a 62.5% overall response rate and 29.2% complete response rate in a Phase 2 frontline advanced melanoma trial of lifileucel plus pembrolizumab.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments